person · Reporting owner
Donovan Michael Patrick
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date March 16, 2024 · Filed March 26, 2024
Section 16 reporting ended · disclosed 2024-03-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,708 |
Reported balance
After 2024-03-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-16 · Exercise / conversion · Acquired 3,000 · Balance 38,708 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 37,992 |
Reported balance
After 2024-03-21 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-21 · Sale · Disposed 716 · Balance 37,992 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 40,942 |
Reported balance
After 2024-03-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2024-03-16 · Exercise / conversion · Acquired 2,950 · Balance 40,942 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 40,221 |
Reported balance
After 2024-03-21 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2024-03-21 · Sale · Disposed 721 · Balance 40,221 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 58,846 |
Reported balance
After 2024-03-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2024-03-16 · Exercise / conversion · Acquired 18,625 · Balance 58,846 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 54,250 |
Reported balance
After 2024-03-21 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2024-03-21 · Sale · Disposed 4,596 · Balance 54,250 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-16 · Exercise / conversion · Disposed 3,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,950 |
Reported balance
After 2024-03-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-16 · Exercise / conversion · Disposed 2,950 · Balance 2,950 F3: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 18,625 |
Reported balance
After 2024-03-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-16 · Exercise / conversion · Disposed 18,625 · Balance 18,625 F3: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 16, 2024.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.
F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 4,596 | $7.68 | $35,297.28 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 6 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,250 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 721 | $7.68 | $5,537.28 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 4 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,221 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 716 | $7.68 | $5,498.88 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,992 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 18,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · derivative · entry 9 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,625 Underlying: Common Stock · 18,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · derivative · entry 8 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,950 Underlying: Common Stock · 2,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · derivative · entry 7 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 18,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 5 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:33 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 36,310 | $8.81 | $319,891.10 |
DisclosureSEC source: 0000805928-24-000041 · wk-form4_1709937172.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,708 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.74 to $8.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 13, 2023 Filed Oct 14, 2023 00:29 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 1,403 | $4.04 | $5,668.12 |
DisclosureSEC source: 0000805928-23-000139 · wk-form4_1697243344.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,018 F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale. Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:29 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000139 · wk-form4_1697243344.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,421 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 48,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000032 · wf-form4_167936133323137.xml · derivative · entry 8 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,500 Underlying: Common Stock · 48,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F7 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F7 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 63,500 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000805928-23-000032 · wf-form4_167936133323137.xml · derivative · entry 7 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,500 Underlying: Common Stock · 63,500 shares Expires 2033-03-16 F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000032 · wf-form4_167936133323137.xml · derivative · entry 6 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 Underlying: Common Stock · 5,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000032 · wf-form4_167936133323137.xml · derivative · entry 5 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,835 | $8.27 | $15,175.45 |
DisclosureSEC source: 0000805928-23-000032 · wf-form4_167936133323137.xml · nonDerivative · entry 4 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,850 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000032 · wf-form4_167936133323137.xml · nonDerivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 934 | $8.27 | $7,724.18 |
DisclosureSEC source: 0000805928-23-000032 · wf-form4_167936133323137.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,785 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000032 · wf-form4_167936133323137.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 02:01 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000147 · wf-form4_167236565329566.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 02:01 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 286 | $9.44 | $2,699.84 |
DisclosureSEC source: 0000805928-22-000147 · wf-form4_167236565329566.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,719 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 02:01 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000147 · wf-form4_167236565329566.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This reflects the number of restricted stock units that vested on December 27, 2022. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 19:56 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 657 | $8.40 | $5,518.80 |
DisclosureSEC source: 0000805928-22-000088 · wf-form4_165834694953675.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,855 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 19:56 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000088 · wf-form4_165834694953675.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,512 F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 34,745 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · derivative · entry 5 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,745 Underlying: Common Stock · 34,745 shares Expires 2032-03-16 F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 37,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · derivative · entry 4 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,250 Underlying: Common Stock · 37,250 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,512 | $7.97 | $12,050.64 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,941 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 5,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0000805928-22-000021 · wf-form4_164573697659302.xml · derivative · entry 4 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2023-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 10,000 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0000805928-22-000021 · wf-form4_164573697659302.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,000 | $5.45 | $27,250.00 |
DisclosureSEC source: 0000805928-22-000021 · wf-form4_164573697659302.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 10,000 | $5.09 | $50,900.00 |
DisclosureSEC source: 0000805928-22-000021 · wf-form4_164573697659302.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 205 | $8.42 | $1,726.10 |
DisclosureSEC source: 0000805928-22-000009 · wf-form4_164513199641018.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,453 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 675 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000009 · wf-form4_164513199641018.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,658 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:21 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000180 · wf-form4_164081287971437.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 2,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:21 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 286 | $9.74 | $2,785.64 |
DisclosureSEC source: 0000805928-21-000180 · wf-form4_164081287971437.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,983 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:21 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000180 · wf-form4_164081287971437.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000174 · wf-form4_164020706647634.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 95 | $9.24 | $877.80 |
DisclosureSEC source: 0000805928-21-000174 · wf-form4_164020706647634.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,119 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:04 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000174 · wf-form4_164020706647634.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 18, 2021. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,935 | $20.04 | $38,777.40 |
DisclosureSEC source: 0000805928-21-000150 · wf-form4_162707076778290.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,839 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 20:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 637 | $19.20 | $12,230.40 |
DisclosureSEC source: 0000805928-21-000147 · wf-form4_162689851942225.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,774 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000147 · wf-form4_162689851942225.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,411 F1 · shares: This reflects the number of shares that became vested as of July 19, 2021 upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:55 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000063 · wf-form4_161610451243588.xml · derivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 11,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:55 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 23,500 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0000805928-21-000063 · wf-form4_161610451243588.xml · derivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,808 | $19.15 | $34,623.20 |
DisclosureSEC source: 0000805928-21-000032 · wf-form4_161376909732872.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,839 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.04 to $19.23, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 207 | $18.71 | $3,872.97 |
DisclosureSEC source: 0000805928-21-000025 · wf-form4_161368661151954.xml · nonDerivative · entry 4 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,647 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:17 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 590 | $18.71 | $11,038.90 |
DisclosureSEC source: 0000805928-21-000025 · wf-form4_161368661151954.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,179 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.